COMPANIES & PRODUCTS

Pfizer
 Table of Contents

01 Global positioning Pfizer's top products based on revenue 2023 21

Pharmaceutical market: worldwide revenue 2001-2023 03

04 Competitors
Top 50 pharmaceutical companies - Rx sales and R&D spending 2022 04
World's most valuable pharmaceutical brands 2023 by brand value 05 AbbVie's revenue 2010-2023 23

Top pharma companies worldwide by number of originated drugs 2023 06 Merck & Co - total revenue 2006-2023 24

Largest M&A pharmaceutical deals ever as of 2024 07 Revenue of Sanofi 2006-2023 25

Sales forecast of top pharmaceutical companies worldwide 2028 08 Johnson & Johnson's total sales 2005-2023 26

Top global biopharma drugs by lifetime sales up to 2028 09 Roche Group's total sales 2006-2023 27

02 Key company data 05 COVID-19

Pfizer's total revenue 2006-2023 11 COVID-19 vaccine dose numbers by top manufacturer 2021 29

Pfizer's net income 2006-2023 12 Pfizer/BioNTech COVID-19 vaccines delivered by country income group 2021 30

Earnings per Pfizer share 2008-2023 13 COVID-19 vaccinations administered in the U.S. as of April 2023, by manufacturer 31

Pfizer's expenditure on research and development 2006-2023 14 BARDA funding for the development of COVID-19 vaccines in the U.S. 2021 32

Pfizer's total assets 2006-2023 15 Comparison of select COVID-19 vaccines 2022, by efficacy 33

Pfizer's total number of employees 2006-2023 16 Comparison of select COVID-19 vaccines worldwide 2022, by efficacy against Delta 34

03 Business distribution
Pfizer's revenues in global submarkets 2010-2023 18
Pfizer's revenues in the U.S. and abroad 2009-2023 19
Pfizer's revenue by segment 2022-2023 20

1
CHAPTER 01

Global positioning
 Revenue of the worldwide pharmaceutical market from 2001 to 2023 (in
billion U.S. dollars)
Pharmaceutical market: worldwide revenue 2001-2023

1,800
1,607
1,600
1,450 1,482
1,400
1,278 1,312
Revenue in billion U.S. dollars

1,214
1,200 1,116 1,135
1,064 1,073
963 964 994
1,000
888
799 831
800 726
649
601
600 560
498
428
390
400

200

0
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023

3 Description: The global pharmaceutical market has experienced significant growth in recent years. For 2023, the total global pharmaceutical market was estimated at around 1.6 trillion U.S. dollars. This is an increase of over 100 billion dollars compared to 2022. Read
more
Note(s): Worldwide
Source(s): IQVIA
 Leading 50 global pharmaceutical companies by prescription sales and
R&D spending in 2022 (in billion U.S. dollars)
Top 50 pharmaceutical companies - Rx sales and R&D spending 2022

Sales/spending in billion U.S. dollars

Research and development spending Prescription sales

0 10 20 30 40 50 60 70 80 90 100

Pfizer (U.S.) 12.38

91.3
AbbVie (U.S.) 6.44
56.18
Johnson & Johnson (U.S.) 14.14
50.17
Novartis (Switzerland) 9.09
50.08
Merck & Co. (U.S.) 11.84
49.63
Roche (Switzerland) 14.78
47.91
Bristol Myers Squibb (U.S.) 10.02
45.42
AstraZeneca (UK) 9.5
43
Sanofi (France) 7.16
40.35
GSK (UK) 6.34
38.25
Takeda (Japan) 4.7
29.69
Gilead Sciences (U.S.) 4.97
26.62
Eli Lilly (U.S.) 7.19
25.46
Novo Nordisk (Denmark) 3.45
25.38

4 Description: The top 50 pharmaceutical companies by prescription sales in 2022 - and their research and development (R&D) spending - included big names such as Pfizer, Novartis, and AbbVie. During that year, Pfizer's Rx sales were approximately 91 billion dollars.
Thus, the American pharma giant was both the largest pharmaceutical company based on pure pharma revenue worldwide and the third ranked pharmaceutical company based on R&D spending. Pfizer spent 12.38 billion U.S. dollars on [...] Read more
Note(s): Worldwide
Source(s): Evaluate (EvaluatePharma); Pharmaceutical Executive; Various sources (company data)
 Most valuable pharmaceutical brands worldwide as of 2023 (in billion U.S.
dollars)
World's most valuable pharmaceutical brands 2023 by brand value

Value in billion U.S. dollars

0 2 4 6 8 10 12 14

Johnson & Johnson 12.8

Roche 8.5

Pfizer 6.2

Merck & Co. 5.8

AstraZeneca 5.6

Bayer 5.5

Bristol Myers Squibb 4.4

Sanofi 4.1

Eli Lilly 3.9

AbbVie 3.9

5 Description: U.S. multinational company Johnson & Johnson maintained its position as the world`s most valuable pharmaceutical brand in 2023. The company`s brand value was estimated at 12.8 billion U.S. dollars, a brand value change of minus five percent
compared to the previous year. Swiss company Roche was ranked second with a brand value of 8.5 billion dollars. Read more
Note(s): Worldwide
Source(s): Brand Finance
 Leading 15 pharmaceutical companies worldwide by number of originated
drugs as of 2023
Top pharma companies worldwide by number of originated drugs 2023

Number of originated drugs

Novartis 112

Roche 110

Pfizer 105

Jiangsu Hengrui Pharmaceuticals 96

Bristol-Myers Squibb 96

AstraZeneca 85

Johnson & Johnson 84

Sanofi 82

Boehringer Ingelheim 75

Merck & Co. 72

Eli Lilly 64

Bayer 63

Takeda 61

GSK 60

Gilead Sciences 59

6 Description: As of beginning of 2023, Swiss company Novartis had 112 originated drugs, making it the company with the highest number of originated drug worldwide that year. Read more
Note(s): Worldwide; as of January 2023
Source(s): Pharma Intelligence (Citeline)
 Largest pharmaceutical industry mergers and acquisitions ever worldwide
until early 2024 (in billion U.S. dollars)
Largest M&A pharmaceutical deals ever as of 2024

Deal value in billion U.S. dollars

0 10 20 30 40 50 60 70 80 90 100

Warner-Lambert (Pfizer, 1999) 87.3

Celgene (Bristol-Myers Squibb, 2019) 74

Aventis SA (Sanofi, 2004) 73.5

Target (acquirer, year)

SmithKline Beechan (Glaxo, 2000) 72.4

Actavis (Allergan, 2015) 65

Pharmacia (Pfizer, 2002) 64.3

Wyeth (Pfizer, 2009) 64.2

Allergan (AbbVie, 2019) 63

Shire (Takeda, 2018) 62

Genentech (Roche, 2009) 46.8

7 Description: As of early 2024, the largest deal in pharmaceutical industry history was Pfizer`s acquisition of Warner-Lambert for nearly 90 billion U.S. dollars in 2000. A further two deals in the rankings involve the American company Pfizer: its acquisitions of rival firms
Pharmacia (2002) and Wyeth (2009). No M&A deal from the 2020s made it into the top list so far. The most recent big deals were the acquisitions of Allergan by AbbVie and of Celgene by Bristol-Myers Squibb, both in 2019. In 2023, the largest [...] Read more
Note(s): Worldwide; as of January 2024
Source(s): Bloomberg; FiercePharma; Forbes; Statista
 Sales forecast of leading 10 pharmaceutical companies worldwide in 2028
(in billion U.S. dollars)
Sales forecast of top pharmaceutical companies worldwide 2028

Sales in billion U.S. dollars

0 10 20 30 40 50 60 70

AbbVie 65.7

Roche 65

Johnson & Johnson 62.3

Merck & Co 59.7

Pfizer 57.1

Novartis 55.2

AstraZeneca 54.5

Sanofi 50.8

Bristol Myers Squibb 44.3

GlaxoSmithKline 44

8 Description: In 2028, U.S.-based pharmaceutical company AbbVie is expected to generate nearly 66 billion U.S. dollars in sales revenue through prescription drugs, making it the world's top drug manufacturer. This statistic illustrates the sales forecast of the leading 10
pharmaceutical companies worldwide in 2028. Read more
Note(s): Worldwide; as of May 2022
Source(s): Evaluate Vantage
 Projected leading 10 pharmaceutical products worldwide based on
lifetime sales as of 2028 (in billion U.S. dollars)
Top global biopharma drugs by lifetime sales up to 2028

Lifetime sales from launch in billion U.S. dollars

Sales until end-2022 Sales 2023-2028 (forecast)

0 50 100 150 200 250 300

Humira (2003)

Keytruda (2015)
Drug name (launch year)

Lipitor (1997)

Enbrel (1998)

Comirnaty (2020)

Remicade (1998)

Rituxan (1997)

Opdivo (2014)

Eliquis (2011)

Eylea (2011)

9 Description: Lipitor, which was introduced by Pfizer back in 1997, is expected to be the drug with the third highest lifetime sales at the end of 2028. As of end-2022, the cholesterol-lowering drug aggregated lifetime sales of 172 billion U.S. dollars, which is expected to
increase for some additional six billion dollars until 2028. Read more
Note(s): Worldwide; as of January 2023
Source(s): Evaluate; Evaluate Vantage
CHAPTER 02

Key company data

 Pfizer's total revenue from 2006 to 2023 (in million U.S. dollars)
Pfizer's total revenue 2006-2023

120,000

100,330
100,000
Revenue in millions of U.S. dollars

81,288
80,000

65,165 65,259
58,496
60,000 54,657
51,584 49,605 52,824 52,546 53,647 51,750
48,371 47,733 47,529 49,078 48,851
41,651
40,000

20,000

0
2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020* 2021 2022 2023

11 Description: Pfizer is a global pharmaceutical company and among the top pharmaceutical companies in the world. Pfizer is headquartered in New York City. In 2022, the company's total revenue exceeded 100 billion U.S. dollars for the first time, a record among
global drug manufacturers. However, in 2023, revenues dropped dramatically to around 58 billion dollars. Read more
Note(s): Worldwide
Source(s): Pfizer
 Pfizer's net income from 2006 to 2023 (in million U.S. dollars)
Pfizer's net income 2006-2023

35,000
31,372

30,000
Net income in million U.S. dollars

25,000
22,003 21,979
21,308
19,337
20,000
16,026
14,570
15,000
11,153
10,009
10,000 8,635 9,135 9,159
8,144 8,104 8,257
6,960 7,215

5,000
2,119

0
2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023

12 Description: The net income of Pfizer stood at some 2.1 billion U.S. dollars in 2023. In the preceding year, the net income was at over 31 billion U.S dollars. Read more
Note(s): Worldwide
Source(s): Pfizer
 Earnings per Pfizer share from 2008 to 2023 (in U.S. dollars)
Earnings per Pfizer share 2008-2023

6
5.59

5
Net earnings per common share

3.92
4
3.57
3.23
2.88
3

1.96 1.9
2 1.65
1.44
1.2 1.23 1.28 1.18
1.03 1.13
1
0.38

0
2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023

13 Description: Pfizer generated a net income of approximately 2.1 billion U.S. dollars in 2022. The company reported basic net earnings per common share of 0.38 U.S. dollars. Read more
Note(s): Worldwide
Source(s): Pfizer
 Pfizer's expenditure on research and development from 2006 to 2023 (in
million U.S. dollars)
Pfizer's expenditure on research and development 2006-2023

12,000 11,428
10,679
10,360
10,000 9,483
9,074
Expenditure in million U.S. dollars

8,557 8,709
8,393 8,385
8,071 7,887 7,870 7,892
7,599 7,690 7,683 7,760
8,000
6,678

6,000

4,000

2,000

0
2006* 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020* 2021* 2022 2023

14 Description: Pfizer is a multinational pharmaceutical company that is headquartered in New York City, New York. Pfizer`s expenditures on research and development (R&D) have been variable in recent history. During 2023, Pfizer spent some 10.7 billion U.S. dollars on
R&D efforts. This is a decrease of around 800 million dollars compared to the previous year. Read more
Note(s): Worldwide
Source(s): Pfizer
 Pfizer's total assets from 2006 to 2023 (in million U.S. dollars)
Pfizer's total assets 2006-2023

250,000
226,501
212,949
195,014 197,205
200,000
Total assets in millions of U.S. dollars

184,629 182,974 181,476

170,415 167,566 167,381 171,615 171,797 167,489
159,422
154,229
150,000

115,546 115,268 111,148

100,000

50,000

0
2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023

15 Description: The statistic shows the total assets of pharmaceutical company Pfizer from 2006 to 2023. Pfizer Inc. is a multinational pharmaceutical corporation. The company is headquartered in Midtown Manhattan, New York City. In 2023, Pfizer's total assets came to
some 227 billion U.S. dollars. Read more
Note(s): Worldwide
Source(s): Pfizer
 Pfizer's number of employees from 2006 to 2023
Pfizer's total number of employees 2006-2023

140,000

120,000 116,500
110,600
103,700
98,000 97,900 96,500
100,000
91,500 90,200 92,400 88,300 88,000
Number of employees

86,600
81,800 83,000
77,700 78,300 78,500 79,000
80,000

60,000

40,000

20,000

0
2006 2007 2008 2009 2010 2011 2012 2013* 2014 2015 2016 2017 2018 2019 2020* 2021 2022 2023

16 Description: The statistic shows the number of employees at pharmaceutical company Pfizer from 2006 to 2022. Pfizer Inc. is a multinational pharmaceutical corporation. The company is headquartered in Midtown Manhattan, New York City. In 2023, Pfizer employed
approximately 88,000 persons around the world. The highest number of employees at Pfizer was reported in 2009, with almost 117 thousand employed persons. Read more
Note(s): Worldwide
Source(s): Pfizer
CHAPTER 03

Business distribution
 Pfizer's revenues in global submarkets from 2010 to 2023 (in million U.S.
dollars)
Pfizer's revenues in global submarkets 2010-2023

United States Developed Europe Developed Rest of World Emerging Markets

45,000

40,000

35,000
Revenue in million U.S. dollars

30,000

25,000

20,000

15,000

10,000

5,000

0
2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020* 2021 2022 2023

18 Description: Sales from the United States contributed more than 27 billion U.S. dollars towards Pfizer's total revenue of around 58 billion U.S. dollars in 2023. Read more
Note(s): Worldwide
Source(s): Pfizer
 Pfizer's revenues in the U.S. and abroad from 2009 to 2023 (in million U.S.
dollars)
Pfizer's revenues in the U.S. and abroad 2009-2023

U.S. Abroad
120,000

100,000
Revenue in millions of U.S. dollars

80,000
57,857

60,000
51,542
36,310 38,326
35,900 31,408
40,000 26,455 26,520 28,318
27,729 31,310 30,532 27,147
20,669 20,196

20,000 42,473
28,855 26,933 26,369 26,026 25,329 29,746 27,088
21,540 23,086 20,274 19,073 21,704 20,326 21,455

0
2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023

19 Description: Revenues generated from outside of the United States accounted for almost two thirds of Pfizer's total revenue in 2023. During that year, the company generated revenues of roughly 31 billion U.S. dollars in countries outside of the United States. Read
more
Note(s): Worldwide
Source(s): Pfizer
 Pfizer's revenue by segment in 2022 and 2023 (in million U.S. dollars)
Pfizer's revenue by segment 2022-2023

Revenue in million U.S. dollars

2023 2022

0 10,000 20,000 30,000 40,000 50,000 60,000 70,000 80,000

30,589
Primary Care
73,023

14,970
Specialty Care
13,833

11,627
Oncology
12,132

1,310
Business Innovation*
1,342

20 Description: This statistic depicts revenues of pharmaceutical company Pfizer in 2022 and 2023, by segment. The Primary Care segment, which includes the COVID-19 vaccine Comirnaty, is the company's strongest segment. Pfizer Inc. is a multinational pharmaceutical
corporation. The company is headquartered in Midtown Manhattan, New York City. Due to the Upjohn spin-off during 2020 and the Consumer Healthcare business merger with GSK's consumer health segment to form a new joint [...] Read more
Note(s): Worldwide; * Pfizer CentreOne and Pfizer Ignite. Read more
Source(s): Pfizer
 Pfizer's top 10 products based on revenue in 2023 (in million U.S. dollars)
Pfizer's top products based on revenue 2023

Revenue in million U.S. dollars

0 2,000 4,000 6,000 8,000 10,000 12,000

Comirnaty* 11,220

Eliquis* 6,747

Prevnar family 6,440

Ibrance 4,753

Vyndaqel/Vyndamax 3,321

Xeljanz 1,703

Paxlovid 1,279

Xtandi 1,191

Inlyta 1,036

Nurtec ODT/Vydura 928

21 Description: The graph depicts Pfizer's top 10 products based on revenue in 2023. Pfizer Inc. is a multinational pharmaceutical corporation. The company is headquartered in Midtown Manhattan, New York City. In 2023, Pfizer's top product was again COVID-19 vaccine
Comirnaty, although with a dramatic drop in sales from 37.8 billion U.S. dollars in 2022 to 11.2 billion dollars. Read more
Note(s): Worldwide; * Alliance revenues and direct sales. Read more
Source(s): Pfizer
CHAPTER 04

Competitors
 AbbVie's revenue from 2010 and 2023 (in million U.S. dollars)
AbbVie's revenue 2010-2023

70,000

60,000 58,054
56,197
54,318
Revenue in million U.S. dollars

50,000
45,804

40,000
32,753 33,266

30,000 28,216
25,638
22,859
18,790 19,960
20,000 17,444 18,380
15,638

10,000

0
2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023

23 Description: This statistic illustrates the revenue of AbbVie from 2010 to 2023. In 2023, AbbVie garnered revenue totaling some 54.3 billion U.S. dollars. Abbot Laboratories was a U.S.-based global pharmaceutical and healthcare products company, headquartered in
Chicago, Illinois. In January 2013, Abbott was separated into two companies: Abbott Laboratories and AbbVie. Abbott Laboratories is now specialized on medical products, while AbbVie is responsible for research-based pharmaceuticals. On May [...] Read more
Note(s): Worldwide; 2010 to 2023
Source(s): AbbVie
 Total revenue of Merck & Co. from 2006 to 2023 (in million U.S. dollars)
Merck & Co - total revenue 2006-2023

70,000

59,283 60,115
60,000
Revenue in million U.S. dollars

48,047 47,267 48,704

50,000 45,987
44,033
42,237 42,294 41,518
39,498 39,807 40,122 39,121
40,000

30,000 27,428
24,198 23,850
22,636

20,000

10,000

0
2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023

24 Description: The revenue of Merck & Co. increased in 2023, rising from 59.3 billion U.S. dollars in 2022 to approximately 60.1 billion U.S. dollars in 2023. During 2021, Merck spun-off its women`s health, biosimilars and established brands businesses into a new publicly
traded company named Organon & Co. Read more
Note(s): Worldwide
Source(s): Merck & Co.
 Revenue of Sanofi from 2006 to 2023 (in million euros)
Revenue of Sanofi 2006-2023

50,000

45,000 42,997 43,070

40,000 37,761
36,126 36,041
34,743 35,072 34,463
33,389 34,060 33,809
35,000
Revenue in million euros

32,367
29,785 30,693 31,380
30,000 28,373 28,052 27,568

25,000

20,000

15,000

10,000

5,000

0
2006 2007 2008 2009 2010 2011* 2012* 2013 2014 2015 2016** 2017 2018 2019 2020 2021 2022 2023

25 Description: Sanofi is a global leader in healthcare and pharmaceuticals based in Paris, France. In 2023, Sanofi generated over 43 billion euros in revenues, the highest so far. In general, the company`s revenues have been increasing since 2006 when their revenues
were 28.4 billion euros. Read more
Note(s): Worldwide
Source(s): Sanofi
 Johnson & Johnson's total sales from 2005 to 2023 (in million U.S. dollars)
Johnson & Johnson's total sales 2005-2023

100,000
93,775 94,943

90,000 85,159
81,581 82,059 82,584
80,000 76,450
74,331
71,312 70,074 71,890
Revenue in million U.S. dollars

70,000 67,224
63,747 61,897 65,030
61,095 61,587
60,000
53,324
50,514
50,000

40,000

30,000

20,000

10,000

0
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023*

26 Description: In 2023, Johnson & Johnson's generated approximately 95 billion U.S. dollars in sales. This statistic shows the global total sales of Johnson & Johnson from 2005 to 2023. Johnson & Johnson is a multinational company, specialized in pharmaceuticals,
medical devices, and consumer goods. The company is headquartered in New Brunswick, New Jersey. Read more
Note(s): Worldwide
Source(s): Johnson & Johnson
 Total sales of the Roche Group from 2006 to 2023 (in million Swiss francs)
Roche Group's total sales 2006-2023

70,000

61,466 62,801 63,281

58,323 58,716
60,000 56,846
53,299
50,576
49,051
47,473 47,462 48,145
Sales in million Swiss francs

50,000 46,133 45,617 45,499 46,780

42,041 42,531

40,000

30,000

20,000

10,000

0
2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023

27 Description: In 2023, the Roche Group, a Swiss pharmaceutical company, generated 58.7 billion Swiss francs in terms of total sales. This statistic shows the annual sales development of Roche since 2006. Read more
Note(s): Worldwide
Source(s): Roche
CHAPTER 05

COVID-19
 Drug manufacturers with the highest number of ordered COVID-19
vaccine doses as of March 2021 (in million doses)
COVID-19 vaccine dose numbers by top manufacturer 2021

Number of doses in millions

0 500 1,000 1,500 2,000 2,500 3,000 3,500

AstraZeneca/Oxford 3,009

Novavax 1,404

BioNTech/Pfizer 1,220

Moderna 816

Gamaleya 765

Sanofi/GSK 712

Johnson & Johnson 368

Sinovac Biotech 367

CureVac 275

Sinopharm 230

29 Description: As of March 9, 2021, there were pre-purchase agreements for over three billion doses of AstraZeneca/Oxford's vaccine. This vaccine is by far the most sought after COVID-19 vaccine, especially due to its ability to be stored at normal refrigerator
temperatures, while other vaccines might need ultra cold storage. Although still in phase III of clinical trials and without approval, Novavax's vaccine is the one with the second highest number of orders worldwide. Read more
Note(s): Worldwide; as of March 9, 2021
Source(s): Bloomberg
 Share of Pfizer/BioNTech COVID-19 vaccines delivered worldwide as of
September 2021, by country income group
Pfizer/BioNTech COVID-19 vaccines delivered by country income group 2021

90%
79.9%
80%

70%
Share of vaccines delivered

60%

50%

40%

30%

20% 18%

10%
2%
0.1%
0%
High-income countries Upper-middle-income countries Lower-middle-income countries Low-income countries

30 Description: As of September 2021, high-income countries accounted for around 80 percent of total Pfizer/BioNTech vaccines delivered worldwide. The statistic illustrates the share of Pfizer/BioNTech COVID-19 vaccines delivered worldwide as of September 2021, by
country income group. Read more
Note(s): Worldwide; as of September 6, 2021
Source(s): Airfinity; Amnesty International
 Number of COVID-19 vaccine doses administered in the United States as
of April 26, 2023, by vaccine manufacturer
COVID-19 vaccinations administered in the U.S. as of April 2023, by manufacturer

400,000,000
366,905,365

350,000,000
Number of vaccinations administered

300,000,000

250,000,000 232,103,958

200,000,000

150,000,000

100,000,000

50,000,000 36,032,994
20,335,074 19,003,955
87,522 880,756
0
Pfizer-BioNTech Pfizer-BioNTech Moderna Moderna updated J&J/Janssen Novavax Other
updated booster booster

31 Description: As of April 26, 2023, roughly 367 million Pfizer-BioNTech COVID-19 vaccine doses had been administered in the United States. This statistic shows the number of COVID-19 vaccinations administered in the United States as of April 26, 2023, by
manufacturer. Read more
Note(s): United States; As of April 26, 2023
Source(s): CDC
 BARDA funding for the development of COVID-19 vaccines in the United
States as of March 2021 (in million U.S. dollars)
BARDA funding for the development of COVID-19 vaccines in the U.S. 2021

Funding in U.S. million dollars

0 1,000 2,000 3,000 4,000 5,000 6,000 7,000

Pfizer and BioNTech 5,973

Moderna and NIAID* 5,896

Sanofi Pasteur and GlaxoSmithKline 2,073

Johnson & Johnson (Janssen subsidiary) 1,998

Novavax 1,600

AstraZeneca and Oxford University 1,600

Merck and IAVI** 143

32 Description: According to data as of March 2021, around six billion U.S. dollars were paid to Pfizer and BioNtech by the Biomedical Advanced Research and Development Authority of the United States to support the development of their COVID-19 vaccine. This
statistic illustrates the BARDA funding for the development of select COVID-19 vaccines in the United States. Read more
Note(s): United States; as of March 2, 2021
Source(s): US Congressional Budget Office; US Department of Health and Human Services
 Comparison of select COVID-19 vaccines worldwide as of 2022, by efficacy
Comparison of select COVID-19 vaccines 2022, by efficacy

Efficacy rate
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%

Comirnaty (Pfizer/BioNTech) 95%

Spikevax (Moderna) 94%

Nuvaxovid (Novavax) 89%

Vaxzevria (AstraZeneca) 70%

JNJ-78436735 (Johnson & Johnson) 66%

Sanofi-GSK vaccine (Sanofi/GlaxoSmithKline) 58%

33 Description: As of February 2022, mRNA-based vaccine Comirnaty, developed by Pfizer/Biontech, was the leading COVID-19 vaccine by efficacy rate, showing around 95 percent of efficacy against COVID-19. This statistic illustrates the comparison of select COVID-19
vaccines worldwide, by efficacy. Read more
Note(s): Worldwide; as of February 2022
Source(s): Evaluate Vantage; Lancet; NEJM; Various sources (company releases)
 Comparison of select COVID-19 vaccines worldwide as of 2022, by efficacy
against Delta variant
Comparison of select COVID-19 vaccines worldwide 2022, by efficacy against Delta

Efficacy rate
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%

Comirnaty (Pfizer/BioNTech) 88%

Spikevax (Moderna) 87%

Nuvaxovid (Novavax) 82%

Sanofi-GSK vaccine (Sanofi/GlaxoSmithKline)* 77%

JNJ-78436735 (Johnson & Johnson) 71%

Vaxzevria (AstraZeneca) 67%

34 Description: As of February 2022, the latest COVID-19 vaccine by Sanofi/GlaxoSmithKline showed a 77 percent efficacy against the Delta variant of the coronavirus. This statistic illustrates the comparison of select COVID-19 vaccines worldwide, by their efficacy against
the Delta variant. Read more
Note(s): Worldwide; as of February 2022; * Early data, sequencing still in progress. Read more
Source(s): BMJ Open; Evaluate Vantage; NEJM; Various sources (company releases)
 Sources

AbbVie Pharmaceutical Executive

Airfinity Roche
Amnesty International Sanofi
Bloomberg Statista
BMJ Open US Congressional Budget Office
Brand Finance US Department of Health and Human Services
CDC Various sources (company data)
Evaluate Various sources (company releases)
Evaluate (Evaluate Pharma)
Evaluate (EvaluatePharma)
Evaluate Vantage
Evaluate Vantage (Evaluate Pharma)
FiercePharma
Forbes
IQVIA
Johnson & Johnson
Lancet
Merck & Co.
NEJM
Pfizer
Pharma Intelligence (Citeline)
Pharma Intelligence (Pharmaprojects)

35